Green tea halts progression of cardiac transthyretin amyloidosis: An observational report

Clinical Research in Cardiology

Volumn 101, Issue 10, 2012, Pages 805-813

  Kristen, Arnt V ^a   Lehrke, Stephanie ^a   Buss, Sebastian ^a   Mereles, Derliz ^a   Steen, Henning ^a   Ehlermann, Philipp ^a   Hardt, Stefan ^a   Giannitsis, Evangelos ^a   Schreiner, Rupert ^b   Haberkorn, Uwe ^c   Schnabel, Philipp A ^c   Linke, Reinhold P ^d   Röcken, Christoph ^e   Wanker, Erich E ^f   Dengler, Thomas J ^g   Altland, Klaus ^a   Katus, Hugo A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Laboratory Dr Limbach   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Reference Center of Amyloid Diseases   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Cardiomyopathy Green tea; Epigallocatechin 3 gallate; Transthyretin derived amyloidosis

Indexed keywords

EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREALBUMIN;

AGED; AMYLOIDOTIC TRANSTHYRETIN CARDIOMYOPATHY; ARTICLE; ARTIFICIAL VENTILATION; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR MAGNETIC RESONANCE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DEFIBRILLATOR; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE WALL; HEART TRANSPLANTATION; HEMOFILTRATION; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; MALE; OBSERVATIONAL STUDY; RECURRENT INFECTION; SINUS NODE; TEA; WHOLE BODY MRI; WHOLE BODY SCINTISCANNING;

AGED; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; CATECHIN; CHOLESTEROL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; PLANT EXTRACTS; TEA;

EID: 84869109959     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-012-0463-z     Document Type: Article

References (60)

1. Ikeda S (2004) Cardiac amyloidosis: Heterogenous pathogenic backgrounds. Intern Med 43:1107-1114
2. Suhr OB, Lindqvist P, Olofsson BO, Waldenstrom A, Backman C (2006) Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy. Amyloid 13:154-159
3. Cornwell GG III, Murdoch WL, Kyle RA, Westermark P, Pitkanen P (1983) Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 75:618-623
4. Puille M, Altland K, Linke RP, Klett R, Bauer R (2002) Tc99 m-DPD scintigraphy in transthyretin-type amyloidosis. Presented at the 5th Internat. Symposium on Familial Amyloidotic Polyneuropathy and Other Related Disorders, Sept 25-27, 2002 Matsumoto, Japan
5. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients. Blood 118:4346-4352
6. Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, Uchino M, Suhr OB (2009) Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival. Liver Transpl 15:1229-1235
7. Hornsten R, Wiklund U, Olofsson BO, Jensen SM, Suhr OB (2004) Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation 78:112-116
8. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW (2006) Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 22:609-618
9. Baures PW, Oza VB, Peterson SA, Kelly JW (1999) Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 7:1339-1347
10. Lueprasitsakul W, Alex S, Fang SL, Pino S, Irmscher K, Kohrle J, Braverman LE (1990) Flavonoid administration immediately displaces thyroxine (T4) from serum transthyretin, increases serum free T4, and decreases serum thyrotropin in the rat. Endocrinology 126:2890-2895
11. Maia F, Almeida MR, Gales L, Kijjoa A, Pinto MM, Saraiva MJ, Damas AM (2005) The binding of xanthone derivatives to transthyretin. Biochem Pharmacol 70:1861-1869
12. Altland K, Winter P, Saraiva MJ, Suhr O (2004) Sulfite and base for the treatment of familial amyloidotic polyneuropathy: Two additive approaches to stabilize the conformation of human amyloidogenic transthyretin. Neurogenetics 5:61-67
13. Altland K, Richardson SJ (2009) Histidine 31: The Achilles' Heel of human transthyretin. Microheterogeneity is not enough to understand the molecular causes of amyloidgenicity. In: Richardson SJ, Cody V (eds) Recent advances in transthyretin evolution, structure and biological function. Springer, Berlin- Heidelberg, pp 201-214
14. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE (2008) EGCG redirects amyloidogenic polypeptides into unstructured, offpathway oligomers. Nat Struct Mol Biol 15:558-566
15. Ferreira N, Cardoso I, Domingues MR, Vitorino R, Bastos M, Bai G, Saraiva MJ, Almeida MR (2009) Binding of epigallocatechin- 3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett 19 583:3569-3576
16. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 107:7710-7715
17. Ferreira N, Saraiva MJ, Almeida MR (2012) Epigallocatechin-3- gallate as a potential therapeutic drug for TTR-related amyloidosis: ''in vivo'' evidence from FAP mice models. PLoS ONE 7:e29933
18. Hunstein W (2007) Epigallocathechin-3-gallate in AL amyloidosis: A new therapeutic option? Blood 110:2216
19. Mereles D, Wanker EE, Katus HA (2008) Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol 97:341-344
20. Mereles D, Buss SJ, Hardt SE, Hunstein W, Katus HA (2010) Effects of the main green tea polyphenol epigallocatechin-3- gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 99:483-490
21. Declaration of Helsinki (1967) Recommendations guiding doctors in clinical research. Adopted by the World Medical Association in 1964. Wiss Med J 66:25-26
22. Eriksson M, Buttner J, Todorov T, Yumlu S, Schonland S, Hegenbart U, Kristen AV, Dengler T, Lohse P, Helmke B, Schmidt H, Rocken C (2009) Prevalence of germline mutations in the TTR gene in a consecutive series of surgical pathology specimens with ATTR amyloid. Am J Surg Pathol 33:58-65
23. Schroder R, Deckert M, Linke RP (2009) Novel isolated cerebral ALlambda amyloid angiopathy with widespread subcortical distribution and leukoencephalopathy due to atypical monoclonal plasma cell proliferation, and terminal systemic gammopathy. J Neuropathol Exp Neurol 68:286-299
24. Altland K, Benson MD, Costello CE, Ferlini A, Hazenberg BP, Hund E, Kristen AV, Linke RP, Merlini G, Salvi F, Saraiva MJ, Singer R, Skinner M, Winter P (2007) Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis 28:2053-2064
25. Puille M, Altland K, Linke RP, Steen Muller MK, Kiett R, Steiner D, Bauer R (2002) 99mTc-DPD scintigraphy in transthyretin- related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 29:376-379
26. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, Longhi S, Lorenzini M, Reggiani LB, Gagliardi C, Gallo P, Villani C, Salvi F (2011) Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretinrelated cardiac amyloidosis. JACC Cardiovasc Imaging 4:659- 670
27. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10(th) International Symposium on Amyloid and Amyloidosis. Am J Hematol 79:319-328
28. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N (1986) Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 57:450-458
29. Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: Part I: Diagnosis, prognosis, and measurements of diastolic function. Circulation 105:1387- 1393
30. Lehrke S, Steen H, Kristen AV, Merten C, Lossnitzer D, Dengler TJ, Katus HA, Giannitsis E (2009) Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: New evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid 16:187-195
31. Henning SM, Niu Y, Liu Y, Lee NH, Hara Y, Thames GD, Minutti RR, Carpenter CL, Wang H, Heber D (2005) Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem 16:610-616
32. Tanabe N, Suzuki H, Aizawa Y, Seki N (2008) Consumption of green and roasted teas and the risk of stroke incidence: Results from the Tokamachi-Nakasato cohort study in Japan. Int J Epidemiol 37:1030-1040
33. Lee SM, Kim CW, Kim JK, Shin HJ, Baik JH (2008) GCG-rich tea catechins are effective in lowering cholesterol and triglyceride concentrations in hyperlipidemic rats. Lipids 43:419-429
34. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI, Low DT (2008) Safety of green tea extracts : A systematic review by the US Pharmacopeia. Drug Saf 31:469-484
35. Herlenius G, Wilczek HE, Larsson M, Ericzon BG (2004) Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: Results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 77:64-71
36. Haagsma EB, Van Gameren II, Bijzet J, Posthumus MD, Hazenberg BP (2007) Familial amyloidotic polyneuropathy: Long-term follow-up of abdominal fat tissue aspirate in patients with and without liver transplantation. Amyloid 14:221-226
37. Okamoto S, Yamashita T, Ando Y, Ueda M, Misumi Y, Obayashi K, Horibata Y, Uchino M (2008) Evaluation of myocardial changes in familial amyloid polyneuropathy after liver transplantation. Intern Med 47:2133-2137
38. Garcia-Herola A, Prieto M, Pascual S, Berenguer M, Lopez- Viedma B, Mir J, Vilchez JJ, Berenguer J (1999) Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. Liver Transpl Surg 5:246-248
39. Liepnieks JJ, Benson MD (2007) Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 14:277-282
40. Miyata M, Sato T, Kugimiya M, Sho M, Nakamura T, Ikemizu S, Chirifu M, Mizuguchi M, Nabeshima Y, Suwa Y, Morioka H, Arimori T, Suico MA, Shuto T, Sako Y, Momohara M, Koga T, Morino-Koga S, Yamagata Y, Kai H (2010) The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry 49:6104-6114
41. Ferreira N, Saraiva MJ, Almeida MR (2011) Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett 585:2424-2430
42. Benson MD, Teague SD, Kovacs R, Feigenbaum H, Jung J, Kincaid JC (2011) Rate of progression of transthyretin amyloidosis. Am J Cardiol 108:285-289
43. Morner S, Hellman U, Suhr OB, Kazzam E, Waldenstrom A (2005) Amyloid heart disease mimicking hypertrophic cardiomyopathy. J Intern Med 258:225-230
44. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH (2005) Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 165:1425-1429
45. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S (2009) Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. Circulation 120:1203-1212
46. Connors LH, Doros G, Sam F, Badiee A, Seldin DC, Skinner M (2011) Clinical features and survival in senile systemic amyloidosis: Comparison to familial transthyretin cardiomyopathy. Amyloid 18(Suppl 1):152-154
47. Kristen AV, Haufe S, Schonland SO, Hegenbart U, Schnabel PA, Rocken C, Hardt S, Lohse P, Ho AD, Haberkorn U, Dengler TJ, Altland K, Katus HA (2011) Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol Jul 15 [epub ahead of print]
48. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ (2000) Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 21:1387-1396
49. Reichek N, Devereux RB, Rocha RA, Hilkert R, Hall D, Purkayastha D, Pitt B (2009) Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. Hypertension 54:731-737
50. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153-158
51. Sohns C, Sossalla S, Schmitto JD, Jacobshagen C, Raab BW, Obenauer S, Maier LS (2010) Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: A comparison between cardiac MRI, invasive measurements and echocardiography. Clin Res Cardiol 99:359-368
52. Yuan J, Qiao S, Zhang Y, You S, Duan F, Hu F, Yang W (2010) Follow-up by cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy who underwent percutaneous ventricular septal ablation. Am J Cardiol 106:1487-1491
53. Prinz C, Farr M, Hering D, Horstkotte D, Faber L (2010) Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry's disease during enzyme-replacement therapy. Clin Res Cardiol 99:53-55
54. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, Voelker W, Ertl G, Wanner C, Strotmann J (2009) Longterm effects of enzyme replacement therapy on fabry cardiomyopathy: Evidence for a better outcome with early treatment. Circulation 119:524-529
55. Al Zahrani GB, Bellavia D, Pellikka PA, Dispenzieri A, Hayman SR, Oh JK, Miyazaki C, Miller FA Jr (2009) Doppler myocardial imaging compared to standard two-dimensional and Doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis. J Am Soc Echocardiogr 22:290-298
56. Butz T, Piper C, Langer C, Wiemer M, Kottmann T, Meissner A, Plehn G, Trappe HJ, Horstkotte D, Faber L (2010) Diagnostic superiority of a combined assessment of the systolic and early diastolic mitral annular velocities by tissue Doppler imaging for the differentiation of restrictive cardiomyopathy from constrictive pericarditis. Clin Res Cardiol 99:207-215
57. Perdrix L, Mansencal N, Cocheteux B, Chatellier G, Bissery A, Diebold B, Mousseaux E, Abergel E (2011) How to calculate left ventricular mass in routine practice? An echocardiographic versus cardiac magnetic resonance study. Arch Cardiovasc Dis 104:343-351
58. Feng WY (2006) Metabolism of green tea catechins: An overview. Curr Drug Metab 7:755-809
59. Altland K, Schreiner R, Hunstein W (2009) Of Green Tea, Black Pepper, and Amyloidoses. www.ukgm.de/ugm-2/deu/ugi-hum/EGCG-Piperin-engl.pdf
60. Suhr O, Danielsson A, Holmgren G, Steen L (1994) Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 235:479-485